

## Expert's Forum Reschedule for November 1, 2009 in Beijing

Excorp Medical, Inc. is pleased to have contracted with the China International Exchange & Promotive Association for Medical and Health Care to coordinate the Expert's Forum rescheduled from October 30<sup>th</sup> to November 1, 2009 in Beijing.

As a necessary, and we believe final, step in negotiations for Asian financing, investors in China have asked that the Company to participate in an "Experts Forum." This is an established mechanism used in China to develop consensus on new medical technology. In this case, the Forum will focus on the nature of the Excorp Medical collaboration on basic science and clinical trials with Chinese universities, and further define the regulatory process required for product approval and commercialization. The prospects for bioartificial liver technology have already been surveyed in China by the organizers of the Forum who have determined that there is a substantial opportunity for our technology in China. (One person dies every 30 seconds of compromised liver function in China!)

While the proceedings of the Forum are protected by a Confidentiality Agreement, outcomes will include a published consensus document and a confirmed regulatory pathway to market approval in China.

The Excorp Medical emphasis on basic science, our animal model of acute liver failure, and the results of our Phase I/II studies with patients at the University of Pittsburgh are perceived to be compelling factors. At least three organizations, including the China Medical Association (<http://www.cma.org.cn>, English page under construction), China Medical Doctors Association (<http://cmdae.org/en/index.php>) and the China International Medical Foundation (CMIF) ([www.cimf.com/Intro](http://www.cimf.com/Intro)) will participate in the Forum. These are quasi-nongovernmental organizations and would offer independent, objective assessment of the bioartificial liver program enhancing the credibility of the findings.

The Expert's Forum will be guided by two of the leading liver health professionals in China. The Chair is Zhuang Hui, MD, Professor, Department of Microbiology, Peking University and Academician, Chinese Academy of Engineering. The Vice Chair is Jia Ji Dong, MD, Ph.D., Professor and Director, Liver Research Center, Beijing Friendship Hospital. (Please see their CVs below)

Attendees will include representatives from The Chinese Academy of Engineering; the Liver Research Center, Beijing Friendship Hospital; the Eastern Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai; a medical statistics expert; and the State Food and Drug Administration (SFDA, China's equivalent to the US FDA).

## Professor Zhuang will Chair the Expert's Forum in Beijing

Focusing on Excorp Medical, Inc., November 1, 2009

### Curriculum Vitae:

Zhuang Hui, male, January 1935-sheng, Han nationality, CCP members, Zhejiang Province, Fenghua City,. 1961 He graduated from the former Soviet Union in 1961, the first medical school in Moscow. 。 In September 1961 to teach at the Zhongshan Medical University; in January 1963 transferred to the work of Peking University Health Science Center since. Successively three times to go to the State of Victoria, Australia infectious diseases reference laboratory (and the World Health Organization reference viruses, bio-security, and collaborative research center) as a visiting scholar. In May 1991 to August first of Japan's University School of Medicine Department of Pathology, a visiting professor. In 2001 was elected as the Chinese Academy of Engineering Faculty Fellow of medical and health. Medicine is now the basis of Pathogenic Biology, Peking University professor in the Department.

1961年毕业于前苏联莫斯科第一医学院。年9月起在中山医科大学任教；1963年1月调入北京大学医学部工作至今先后3次赴澳大利亚维多利亚州立传染病参比实验室（兼世界卫生组织病毒参考、生物安全性和协作研究中心）作访问学者。1991年5月至8月任日本大学医学院第一病理学教研室客座教授。2001年当选为中国工程院医药卫生学部院士。现为北京大学基础医学院病原生物学系教授。庄辉简介 Zhuang Hui Introduction.

### 北京大学 Peking

庄辉（1935.1.17-）流行病学、微生物学专家。Zhuang Hui (1935.1.17-) epidemiology, microbiology experts. 中国工程院院士。 Chinese Academy of Engineering academician. 浙江省奉化市人。 Zhejiang Fenghua City,. 曾任世界卫生组织病毒性肝炎技术咨询小组成员、现任中华预防医学会副会长，北京大学医学部基础医学院病原生物学系教授。

Served as the WHO Technical Advisory Group member of viral hepatitis, the current Chinese Preventive Medical Association, vice president of Peking University Health Science Center School of Basic Medical Department of Pathogen Biology, Professor. Zhuang Hui 1961, in September to teach at the Zhongshan Medical University; in January 1963 transferred to the work of Peking University Health Science Center since. 。 Successively three times to go to the State of Victoria, Australia infectious diseases reference laboratory (and the World Health Organization reference viruses, bio-security, and collaborative research center) as a visiting scholar. In May 1991 to August first of Japan's University School of Medicine Department of Pathology, a visiting professor. Elected in 2001 as the Chinese Academy of Engineering Faculty Fellow of medical and health. Medicine is now the basis of Pathogenic Biology, Peking University professor in the Department. Zhuang Hui successfully developed the "hepatitis E virus IgG antibodies by enzyme-linked immunosorbent assay kit" and "hepatitis B virus surface antigen-colloidal gold test strip" and so on. 。 Academic journals at home and abroad a total of more than 450 papers published articles, participated in the preparation of English monograph 5, Chinese, monographs, more than 30 books, translated with an. Who was the host country "75", "85", "95" research topics; participate in the national "15" research topics, 973 plans, 863 plans, the State Science and Technology special issue of major

national research programs to guide the project, the ratio and the Sino-Japanese cooperation in scientific research topics (the Chinese host), etc.. Is mainly engaged in viral hepatitis research.

庄辉1961年

9月起在中山医科大学任教；1963年1月调入北京大学医学部工作至今。先后3次赴澳大利亚维多利亚州立传染病参比实验室（兼世界卫生组织病毒参考、生物安全性和协作研究中心）作访问学者1991年5月至8月任日本大学医学院第一病理学教研室客座教授。2001年当选为中国工程院医药卫生学部院士。现为北京大学基础医学院病原生物学系教授。庄辉研制成功"戊型肝炎病毒IgG抗体酶联免疫测定试剂盒"和"乙型肝炎病毒表面抗原胶体金试纸条"等。在国内外学术期刊上共发表论文450余篇，参加编写英文专著5册，中文专著30余册，译著1册曾主持国家《七五》、《八五》、《九五》攻关课题；参加国家《十五》攻关课题、973计划、863计划、国家科委重大专项课题、国家科技攻关计划引导项目、中比和中日科研合作课题(中方主持人)等。主要从事病毒性肝炎研究。首先证实中国存在流行性和散发性戊型肝炎；总结了我国戊型肝炎临床和流行病学特征；提出戊型肝炎流行和散发与病毒基因型无关，而与流行因素有关；发现戊型肝炎开放读框3抗原主要与急性期抗体有关，而开放读框2抗原则与恢复期抗体关系密切；在国内首先建立戊型肝炎实验室诊断技术和猕猴动物模型；研制成功“戊型肝炎病毒IgG抗体酶联免疫测定试剂盒”和“乙型肝炎病毒表面抗原胶体金试纸条”等，获三项国家新药证书。

First prove that there is epidemic in China, and sporadic hepatitis E; summed up China's Hepatitis E clinical and epidemiological characteristics; raised the prevalence and distribution of hepatitis E virus genotype with nothing to do with the epidemic factors; found that hepatitis E open reading frame with the 3 major acute phase antigen-antibody related to the open reading frame 2 against the principles and convalescent antibody close; first established in the country of hepatitis E in laboratory diagnostic techniques and monkey animal models; developed "hepatitis E virus IgG antibodies Enzyme-linked immunosorbent assay kit "and" hepatitis B virus surface antigen-colloidal gold test strip "and so on, by three national drug certification. Has won the national scientific and technological progress second prize two, Ministry of Health, scientific and technological progress prize, first prize for scientific and technological progress, Beijing, Zhejiang and the scientific and technological progress prize of a U.S. patent. Academic journals at home and abroad more than 400 papers were published in articles, of which 30 are SCI included, citing more than 250 times. In 2001 was elected as the Chinese Academy of Engineering. Peking University Health Science Center School of Basic Medical microbiology professor and doctoral tutor . World Health Organization Western Pacific Regional Committee of the State Council confirmed that the eradication of polio subjects Degrees Committee evaluation team member of the Leading Group for Hepatitis Control in the Ministry of Health Ministry of Health Expert Advisory Committee on Viral Hepatitis in China Committee on Biological Standardization . The Chinese Medical Association director of the Chinese Medical Association Director of the Institute and members of Liver Diseases .

先后获国家科技进步二等奖两项，卫生部科技进步一等奖、北京市科技进步一等奖、浙江省科技进步一等奖和美国专利各一项。在国内外学术期刊上共发表论文400余篇，其中30篇被SCI收录，引用250余次。2001年当选为中国工程院院士。

北京大学医学部基础医学院微生物学系教授、博士生导师世界卫生组织西太区消灭脊髓灰质炎证实委员会委员国务院学位委员会学科评议组卫生部肝炎防治领导小组成员卫生部病毒性肝炎专家咨询委员会中国生物制品标准化委员会委员中华医学会理事中华医学会肝病学会主任委员等兼任职务

#### Part-time job - Publications

《中华肝脏病杂志》、《《中国公共卫生》和《《国外医学病毒学》杂志》副主编《中华流行病学杂志》 "Chinese Journal of liver disease", "" China's public health "and" "Foreign Medical Virology" magazine, deputy editor of the "Chinese Journal of Epidemiology"

《中华实验和临床病毒学杂志》 "Chinese Journal of Experimental and Clinical Virology"

《中西医结合肝病杂志》 "Journal of Chinese and Western medicine with liver disease"

《中国生物制品学杂志》 "Chinese Journal of Biological Products"

《中国输血杂志》 "Chinese Journal of Blood Transfusion"

《疾病控制杂志》等十余种期刊的常务编委或编委 "Centers for Disease Control magazine," and so on more than ten kinds of journals or the Editorial Board, Managing Editor

#### 曾任职务 Previous posts

世界卫生组织病毒性肝炎技术咨询小组成员国际戊型肝炎研究会副主席亚太地区公共卫生学术联合会理事全国博士后管委会专家组卫生部药品审评委员会委员中华预防医学会常务理事北京医科大学公共卫生学院院长和北京市肝炎研究所副所长等。

World Health Organization Technical Advisory Group members of the Viral Hepatitis Research International Vice-Chairman of the Asia Pacific region public health, academic director of the National Postdoctoral Association of the CMC Group Ministry of Health, Drug Evaluation Committee members will be executive director of the Chinese Preventive Medicine, Beijing Medical University School of Public Health of the President and deputy director of Beijing Institute of hepatitis, etc..

#### 庄辉主要荣誉 Zhuang Hui Main Honors

1999年12月 “乙型肝炎表明抗原胶体金试剂盒” 获中国药品监督管理局颁发的新药证书； In December 1999, "Hepatitis B antigen showed that colloidal gold reagent box" by China's Drug Administration issued a new drug certificate;

1998年8月“戊型肝炎病毒IgG抗体酶联免疫测定试剂盒”获中国药品监督管理局颁发的新药证书； In August 1998, "hepatitis E virus IgG antibodies by enzyme-linked immunosorbent assay kit" by China Drug Administration issued a new drug certificate;

1999年3月“戊型肝炎病毒分子生物学、血清学、诊断及散发性戊型肝炎研究”获国家科技进步二等奖； In March 1999, "Hepatitis E virus, molecular biology, serology, methods of diagnosis and study of sporadic hepatitis E" won the national scientific and technological progress second prize;

1993年12月“戊型肝炎病原学及流行病学研究”获国家科技进步二等奖； In December 1993, "Etiology and Epidemiology of hepatitis E research" won the national scientific and technological progress second prize;

1992年6月“戊型肝炎病原学及流行病学研究”获卫生部科技进步一等奖； In June 1992, "Etiology and Epidemiology of hepatitis E research" first prize for scientific and technological progress by the Ministry of Health;

1997年8月“戊型肝炎病毒分子生物学、血清学及散发性戊型肝炎研究”获卫生部科技进步二等奖； In August 1997, "Hepatitis E virus, molecular biology, serology and sporadic hepatitis E research" scientific and technological progress second prize by the Ministry of Health;

In February 2003 "ImmunoreactiveantigensofhepatitisEvirus" by U.S. patent (US6, 514,690 B1);

2004年6月“新型冠状病毒(N蛋白)测定试剂盒(化学发光法)”获中国药品监督管理局颁发的新药证书；


In June 2004, "new coronavirus (N protein) detection kit (chemiluminescence method)" by China Drug Administration issued a new drug certificate;

2005年1月“戊型肝炎病毒基因4型及其分子生物学和家畜感染研究”获中华医学科技奖一等奖”等。 In January 2005, "Hepatitis E virus gene 4 type and its molecular biology and animal infection study" was the first prize of Chinese Medical Science and Technology "and so on.

## Professor Jia is Vice Chair of the Expert's Forum

focusing on Excorp Medical, November 1, 2009

### Curriculum Vitae



Prof. Jia Ji-dong; Current position: Beijing Friendship Hospital, Capital Medical University Liver Research Center, Capital Medical University, deputy director of the Department of Gastroenterology, Digestive Disease Center, deputy director of Beijing. Part-time Chinese Medical Association, director of liver credits, member of China Association of Integrative Medicine, vice chairman of the Professional Committee of liver disease, digestive Doctor Association Chinese Medical Association Executive Committee and the Asia Pacific Institute of Liver Diseases (APASL), European Institute of Liver (EASL) and the United States Institute of Liver Diseases (AASLD) member. At the same time was appointed editor of Chinese Journal of Hepatology, "Chinese Journal of liver disease" and associate editor of Hepatology Chinese, Journal of Gastroenterology and Hepatology International Editorial Board, and other many professional journal editorial boards.

现任首都医科大学附属北京友谊医院肝病研究中心主任，首都医科大学消化病学系副主任、北京市消化疾病中心副主任。兼任中华医学会肝病学会主任委员、中国中西医结合学会肝病专业委员会副主任委员、中国医师协会消化医师分会执行委员及亚太肝病学会（APASL）、欧洲肝病学会（EASL）及美国肝病学会（AASLD）会员。同时被聘为Journal of Hepatology 中文版主编、《中华肝脏病杂志》及Hepatology中文版副主编，Journal of Gastroenterology and Hepatology国际编委及其它多家专业杂志编委。

1990-1993 School of Medicine in the capital, pursuing a doctorate of Gastroenterology in Germany between 1997-1999 Free University of Berlin, gastrointestinal and liver disease Branch to do postdoctoral research. To Beijing's "New Star Science and Technology Plan," "cross-century project of outstanding

talent" and "Shi Baiqian" outstanding talent project selected who enjoy special government allowance issued by the State Council, an "outstanding contributions of young experts in the Ministry of Health" title

1990—1993年在首都医学院攻读消化内科博士学位，1997—1999年德国柏林自由大学胃肠与肝病科做博士后研究工作。为北京市“科技新星计划”、“跨世纪使优秀人才工程”及“十百千”优秀人才工程入选者，享受国务院颁发的政府特殊津贴,获"卫生部有突出贡献的中青年专家"称号。

Chronic diseases mainly engaged in clinical, research and teaching. In the clinical context, in addition to the standard diagnosis and treatment of various chronic viral hepatitis, the pairs of rare and difficult autoimmune liver disease, cholestatic liver disease, alcohol or drug-induced liver disease, genetic metabolic liver disease and liver transplants before and after internal scientific issues have a higher academic interest. Main research direction with liver fibrosis in chronic liver disease pathogenesis and treatment. Main research content of the liver extracellular matrix biochemistry, cell biology and molecular biology and its application in liver fibrosis and development of the status and role of drugs on the liver synthesis and degradation of extracellular matrix metabolism and so on.

**主要从事慢性病的临床、科研和教学工作。**在临床方面，除各种慢性病毒性肝炎的规范诊治外，对少见和疑难的自身免疫性肝病、胆汁淤积性肝病、酒精或药物性肝病、遗传代谢性肝病以及肝移植手术前后的内科学问题有较高的学术兴趣。主要科研方向为慢性肝病伴肝纤维化的发生机理及治疗。主要**研究内容**为肝脏细胞外基质的生物化学、细胞生物学和分子生物学及其在肝纤维化发生和发展中的地位和作用、药物对肝脏细胞外基质合成与降解代谢的影响等。

Is mainly engaged in viral hepatitis research.